DD7 Kinase Inhibitor Case Studies

Updated

Kinase drug discovery remains to be an area of significant and growing interest across academia and in the pharmaceutical industry - there are approximately 30 FDA approved small molecule inhibitors which target kinases, half of which were approved in the last 3 years. This lecture will give an insight into the medicinal chemistry story behind one clinical candidate and 2 marketed drugs. Crystal structures will be used to explain general principles behind designing for kinase inhibition, and some more advanced topics will be covered such as prodrugs, covalent inhibition and consideration of mutation status in drug discovery

Dr F Goldberg - AstraZeneca

Number of sessions: 1